JP2004512010A - インスリン及びｉｇｆ−１受容体のアゴニスト及びアンタゴニスト - Google Patents

インスリン及びｉｇｆ−１受容体のアゴニスト及びアンタゴニスト Download PDF

Info

Publication number
JP2004512010A
JP2004512010A JP2001571702A JP2001571702A JP2004512010A JP 2004512010 A JP2004512010 A JP 2004512010A JP 2001571702 A JP2001571702 A JP 2001571702A JP 2001571702 A JP2001571702 A JP 2001571702A JP 2004512010 A JP2004512010 A JP 2004512010A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
group
igf
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001571702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004512010A5 (enExample
Inventor
ビースリー、ジェームス
ブルーム、アーサー・ジェイ
シェファー、ラウゲ
ピルトラ、レヌーカ
ブラント、ヤコブ
ブリセッテ、レニー
スペツラー、ヤーネ
チェン、ウェイキン
オステルガールド、ソレン
マンデッキ、ウロデク・エス
ハンセン、ペール・ヘルツ
ラベラ、マーク
シャオ、ク−チュアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2004512010A publication Critical patent/JP2004512010A/ja
Publication of JP2004512010A5 publication Critical patent/JP2004512010A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2001571702A 2000-03-29 2000-03-29 インスリン及びｉｇｆ−１受容体のアゴニスト及びアンタゴニスト Pending JP2004512010A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/008528 WO2001072771A2 (en) 2000-03-29 2000-03-29 Insulin and igf-1 receptor agonists and antagonists

Publications (2)

Publication Number Publication Date
JP2004512010A true JP2004512010A (ja) 2004-04-22
JP2004512010A5 JP2004512010A5 (enExample) 2005-01-27

Family

ID=21741219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001571702A Pending JP2004512010A (ja) 2000-03-29 2000-03-29 インスリン及びｉｇｆ−１受容体のアゴニスト及びアンタゴニスト

Country Status (6)

Country Link
EP (2) EP1383793B1 (enExample)
JP (1) JP2004512010A (enExample)
AT (1) ATE529435T1 (enExample)
AU (1) AU2000239309A1 (enExample)
CA (1) CA2402780A1 (enExample)
WO (1) WO2001072771A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763244B2 (en) 2002-07-01 2010-07-27 Human Genome Sciences, Inc. Antibodies that specifically bind to Reg IV
WO2012160990A1 (ja) * 2011-05-25 2012-11-29 Hoya株式会社 Ｉｇｆ－１ｒ結合性ペプチド

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
DE60217066T4 (de) 2001-02-09 2010-07-01 Genentech, Inc., South San Francisco Kristallisierung von igf-1
CA2439735A1 (en) * 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
AU2003301195B2 (en) * 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
AU2004278311A1 (en) 2003-10-03 2005-04-14 Genentech, Inc. IGF binding proteins
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
WO2006047214A2 (en) * 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
EP2281841A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarkers for pre-selection of patients for anti-IGF1R therapy
PT2360255E (pt) 2005-03-25 2015-04-08 Nat Res Council Canada Método para isolamento de polipéptidos solúveis
AU2006264567A1 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US7659362B2 (en) * 2006-05-30 2010-02-09 Academia Sinica Metal-binding motif compositions and methods
WO2008133961A2 (en) 2007-04-24 2008-11-06 Antyra Inc. Igf-1r binding proteins and antagonists
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
CN111377773A (zh) * 2020-04-16 2020-07-07 山东省现代中药研究院有限公司 一种含内生菌的花生用海藻复合微生物有机肥

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032017A2 (en) * 1997-01-15 1998-07-23 Telik, Inc. Modulators of insulin receptor activity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US6010861A (en) 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
DE4432943A1 (de) * 1994-09-15 1996-03-21 Radulescu Razvan T Dr Med M D Numerical Mirror Image Strategy (NUMIS)
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
JPH11506722A (ja) * 1995-06-07 1999-06-15 ベイラー・カレッジ・オブ・メディスン 細胞に核酸を送達するための核酸運搬体
RU2078769C1 (ru) * 1995-08-18 1997-05-10 Научно-исследовательский институт биомедицинской химии РАМН Пептидный фрагмент, обладающий биологической активностью инсулина
US5912160A (en) * 1995-08-22 1999-06-15 Thomas Jefferson University Gab1, Grb2 binding protein, and compositions for making and methods of using the same
WO1997046683A2 (en) * 1996-06-07 1997-12-11 Genetics Institute, Inc. Polynucleotides encoding secreted proteins
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US7020563B1 (en) * 1997-11-27 2006-03-28 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to IGF receptor
AU2321999A (en) * 1998-01-16 1999-08-02 Genzyme Corporation Adenoviral vectors with modified capsid proteins
WO2000006717A2 (en) * 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032017A2 (en) * 1997-01-15 1998-07-23 Telik, Inc. Modulators of insulin receptor activity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763244B2 (en) 2002-07-01 2010-07-27 Human Genome Sciences, Inc. Antibodies that specifically bind to Reg IV
WO2012160990A1 (ja) * 2011-05-25 2012-11-29 Hoya株式会社 Ｉｇｆ－１ｒ結合性ペプチド

Also Published As

Publication number Publication date
EP1383793A2 (en) 2004-01-28
CA2402780A1 (en) 2001-10-04
WO2001072771A3 (en) 2003-12-04
WO2001072771A2 (en) 2001-10-04
ATE529435T1 (de) 2011-11-15
EP2368902A3 (en) 2011-12-21
AU2000239309A1 (en) 2001-10-08
EP1383793B1 (en) 2011-10-19
EP2368902A2 (en) 2011-09-28

Similar Documents

Publication Publication Date Title
EP1383793B1 (en) Insulin and igf-1 receptor agonists and antagonists
AU2026201801A1 (en) Stabilized Peptide-Mediated Targeted Protein Degradation
US7173005B2 (en) Insulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) Insulin and IGF-1 receptor agonists and antagonists
US20250123275A1 (en) Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use
US20020147306A1 (en) Peptides that modulate the interaction of B class ephrins and PDZ domains
US20030232014A1 (en) Phosphorylated proteins and uses related thereto
WO2002076489A1 (en) Serum albumin binding moieties
JP2003518075A (ja) 生理活性化合物の消失半減期延長のための方法及び組成物
AU2021204400B2 (en) Cystine knot scaffold platform
JP2002509708A (ja) コラーゲンペプチド及びその使用
US6387879B1 (en) Compounds that bind growth to hormone receptor
Chuman et al. Identification of a peptide binding motif for secreted frizzled-related protein-1
US7148193B2 (en) Compounds that bind to growth hormone receptor
Doughty et al. The contribution of helical potential to the in vitro receptor binding activity of a neuropeptide YN‐terminal deletion fragment
US11198715B2 (en) Selective Bfl-1 peptides
Pepanian et al. In-depth characterization of Gαs protein activity by probing different guanine nucleotides
WO2011132940A2 (ko) Rtk에 특이적으로 결합하는 rtk-bpb
JP3922345B2 (ja) 生理活性ペプチド
HK40072594A (en) Cystine knot scaffold platform
KR20130103301A (ko) 전사인자에 특이적으로 결합하는 ｔｆ-ｂｐｂ
Lian Development and Optimization of Protein-Protein Interaction Inhibitors by Combinatorial and Medicinal Chemistry
Raman Protein Design for Construction of Therapeutic Peptides
SEQUENCE-CONTAINING et al. OR03 P682
WO1999065944A1 (en) PEPTIDE INHIBITORS OF αVβ3 AND αVβ¿5?

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100301

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110104